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5 Objective. Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a
356KRAS 3′ UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer
357risk as well as with survival time. However, prior studies, emphasizing particular subgroups, were relatively
358small. Therefore, we comprehensively evaluated ovarian and breast cancer risks as well as clinical outcome asso-
359ciated with rs61764370.
360Methods. Centralized genotyping and analysis were performed for 140,012 women enrolled in the Ovarian
361Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the Breast Cancer Association
362Consortium (33,530 breast cancer patients; 37,640 controls), and the Consortium of Modiﬁers of BRCA1 and
363BRCA2 (14,765 BRCA1 and 7904 BRCA2mutation carriers).
364Results.We foundno associationwith risk of ovarian cancer (OR=0.99, 95% CI 0.94–1.04, p=0.74) or breast
365cancer (OR = 0.98, 95% CI 0.94–1.01, p = 0.19) and results were consistent among mutation carriers (BRCA1,
366ovarian cancer HR = 1.09, 95% CI 0.97–1.23, p = 0.14, breast cancer HR = 1.04, 95% CI 0.97–1.12, p = 0.27;
367BRCA2, ovarian cancer HR = 0.89, 95% CI 0.71–1.13, p = 0.34, breast cancer HR = 1.06, 95% CI 0.94–1.19, p =
3680.35). Null results were also obtained for associations with overall survival following ovarian cancer (HR =
3690.94, 95% CI 0.83–1.07, p = 0.38), breast cancer (HR = 0.96, 95% CI 0.87–1.06, p = 0.38), and all other
370previously-reported associations.
371Conclusions. rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for
372patients with these cancers. Therefore, genotyping this variant has no clinical utility related to the prediction or
373management of these cancers.
374© 2015 Published by Elsevier Inc.
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392
393 1. Introduction
394 MicroRNAs (miRNAs) are a class of small non-coding RNAmolecules
395 that negatively regulate gene expression by binding partially comple-
396 mentary sites in the 3′ untranslated regions (UTRs) of their target
397 mRNAs. In this way, miRNAs control many cancer-related biological
398 pathways involved in cell proliferation, differentiation, and apoptosis
399 [1]. To date, several inherited variants in microRNAs or miRNA target
400 sites have been reported to confer increased cancer risks [2]. One such
401 variant is located in the 3′ UTR of the KRAS gene (rs61764370 T N G)
402 for which the rarer G allele has been reported to confer an increased
403 risk of ovarian, breast, and lung cancer [3–7] as well as endometriosis
404 [8], although not consistently [9–11].
405 For ovarian cancer, the rs61764370 G allele was also reported to be
406 associated with increased risk (320 cases, 328 controls). Further in-
407 creased risks were observed among 23 BRCA1 mutation carriers and
408 31 women with familial ovarian cancer, but without BRCA1 or BRCA2
409 mutations [3]. In contrast, no association with ovarian cancer risk was
410 seen in another, much larger study, based on 8669 cases, 10,012 con-
411 trols, and 2682 BRCA1mutation carriers [9]. One criticism on the latter
412 study was that some of the genotype data were for rs17388148, an
413 imputed proxy for rs61764370; even though rs17388148 is highly
414correlatedwith rs61764370 (r2=0.97) andwas imputed with high ac-
415curacy (r2=0.977) [12,13]. Theminor allele of rs61764370was also as-
416sociated with shorter survival time in a study of 279 ovarian cancer
417patients diagnosed after age 52 years with platinum-resistant disease
418(28 resistant, 263 not resistant) and with sub-optimal debulking sur-
419gery after neoadjuvant chemotherapy (7 sub-optimal, 109 optimal)
420[14]. However, another study observed no association between
421rs61764370 and ovarian cancer outcome (329 cases) [15].
422For breast cancer, a borderline signiﬁcant increased frequency of the
423rs61764370 G allele was observed in 268 BRCA1mutation carriers with
424breast cancer, but not in 127 estrogen receptor (ER)-negative familial
425non-BRCA1/BRCA2 breast cancer patients [5]. However, in a subsequent
426study, the variant was reported to be associated with increased risk of
427ER/PR negative disease (80 cases, 470 controls), as well as with triple
428negative breast cancer diagnosedbefore age 52 (111 cases, 250 controls),
429regardless of BRCA1mutation status [6]. The validity of these ﬁndings has
430been questioned given the very small sample sizes and the number of
431subgroups tested [16,17]. Another report found no association with spo-
432radic or familial breast cancer risk (695 combined cases, 270 controls),
433but found that the variant was associated with ERBB2-positive and
434high grade disease, based on 153 cases who used post-menopausal hor-
435mone replacement therapy [18].
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436 It has also been reported, based on 232 women with both primary
437 ovarian and breast cancer, that the frequency of the G allele at
438 rs61764370 was increased for those who were screened negative for
439 BRCA1 and BRCA2 (92 cases), particularly among those enrolled within
440 two years of their ovarian cancer diagnosis (to minimize survival bias,
441 30 cases), those diagnosed with post-menopausal ovarian cancer (63
442 cases), those with a family history of ovarian or breast cancer (24
443 cases), and those with a third primary cancer (16 cases) [4].
444 This notable lack of consistency in ﬁndings between studiesmight be
445 expected when appropriate levels of statistical signiﬁcance are not used
446 to declare positive ﬁndings from multiple small subgroup comparisons
447 or post-hoc hypotheses [19]. In this respect, the dangers of subgroup
448 analyses in the context of clinical trials are well-recognized [20]. These
449 are important caveats, particularly since a genetic test for rs61764370
450 is currently marketed in the US for risk prediction testing to women
451 who are at increased risk for developing ovarian and/or breast cancer
452 orwomenwhohave been diagnosedwith either ovarian or breast cancer
453 themselves [21]. In general, much larger studies, with sufﬁcient power to
454detect positiveﬁndings atmuchmore stringent levels of statistical signif-
455icance ought to be required to establish the clinical validity of a genetic
456test. Therefore, we conducted centralized genotyping of rs61764370
457and other variants in the genomic region around the KRAS gene in
458140,012 women to examine associations with risk and clinical outcome
459of ovarian and breast cancer.
4602. Methods
4612.1. Study participants
462The following three consortia contributed to these analyses: the
463Ovarian Cancer Association Consortium (OCAC: 41 studies, Supplemen-
464tary Table S1) [22], the Breast Cancer Association Consortium (BCAC: 37
465studies, Supplementary Table S2) [23], and the Consortium ofModiﬁers
466of BRCA1 and BRCA2 (CIMBA: 55 studies, Supplementary Table S3)
467[24,25]. OCAC and BCAC consisted of case–control studies of unrelated
468women, and CIMBA consisted of studies of women with germline
t1:1 Table 1
t1:2 Associations between KRAS rs61764370 and risk of ovarian and breast cancer.
t1:3 For BRCA1 and BRCA2mutation carrier analyses, cases are affected BRCA1/BRCA2mutation carriers and controls are unaffected BRCA1/BRCA2mutation carriers, and relative risks are esti-
t1:4 mated by hazard ratios; for other analyses, relative risks are estimated by odds ratios; ovarian cancer analyses used OCAC data adjusted for study, age, and the ﬁve European principal
t1:5 components; breast cancer analyses used BCAC data adjusted for study, age, and the seven European principal components; BRCA1 and BRCA2mutation carrier analyses used CIMBA data
t1:6 with age as follow-up time and stratiﬁed for country; 95% CI, 95% conﬁdence interval.
t1:7 Number Minor allele frequency Relative risk (95% CI)
t1:8 Cases Controls Cases Controls p-Value
t1:9 Ovarian cancer
t1:10 All invasive 15,357 30,816 0.0914 0.0949 0.99 (0.94–1.04) 0.74
t1:11 Histology
t1:12 High-grade serous 6938 30,816 0.0946 0.0949 1.04 (0.97–1.11) 0.26
t1:13 Endometrioid 2151 30,816 0.0834 0.0949 0.90 (0.80–1.00) 0.06
t1:14 Clear cell 1015 30,816 0.0994 0.0949 1.09 (0.94–1.27) 0.27
t1:15 Mucinous 1000 30,816 0.0902 0.0949 0.99 (0.85–1.16) 0.91
t1:16 Low-grade serous 485 30,816 0.0705 0.0949 0.76 (0.59–0.97) 0.03
t1:17 First-degree family history
t1:18 Ovarian cancer 483 342 0.0803 0.0849 0.87 (0.60–1.27) 0.47
t1:19 Breast or ovarian cancer 477 18,442 0.0977 0.0915 1.09 (0.93–1.28) 0.28
t1:20 BRCA1/2mutation negative 346 15,492 0.1050 0.0997 1.09 (0.85–1.41) 0.49
t1:21 BRCA1mutation carriers 2332 12,433 0.0954 0.0922 1.09 (0.97–1.23) 0.14
t1:22 BRCA2mutation carriers 599 7305 0.0952 0.0966 0.89 (0.71–1.13) 0.34
t1:23 Enrolled within two years of diagnosis
t1:24 All invasive 10,121 30,815 0.0942 0.0949 0.99 (0.95–1.04) 0.68
t1:25 BRCA1mutation carriers 1095 10,802 0.0950 0.0940 1.05 (0.90–1.23) 0.52
t1:26 BRCA2mutation carriers 270 6509 0.0907 0.0979 0.85 (0.60–1.20) 0.36
t1:27 Menopausal status
t1:28 Pre- or peri-menopausal 4264 8789 0.0915 0.0927 1.02 (0.92–1.13) 0.68
t1:29 Post-menopausal 11,058 15,903 0.0916 0.0951 0.99 (0.93–1.06) 0.81
t1:30 Prior breast cancer
t1:31 Enrolled within two years of diagnosis 426 30,815 0.0943 0.0949 0.91 (0.71–1.17) 0.46
t1:32 Post-menopausal ovarian cancer 341 15,903 0.0810 0.0951 0.90 (0.68–1.21) 0.49
t1:33 First degree breast or ovarian cancer family history 202 30,815 0.0916 0.0949 0.99 (0.70–1.40) 0.95
t1:34
t1:35 Breast cancer
t1:36 All invasive 33,530 37,640 0.0904 0.0930 0.98 (0.94–1.01) 0.19
t1:37 Receptor status
t1:38 ER−/PR− 4009 37,043 0.0940 0.0932 1.04 (0.96–1.13) 0.36
t1:39 ER−/PR−/ERBB2− 1673 28,480 0.0885 0.0947 0.97 (0.85–1.10) 0.62
t1:40 First-degree family history
t1:41 Breast cancer 4357 1943 0.0942 0.0954 0.96 (0.84–1.10) 0.59
t1:42 Ovarian or breast cancer 4593 2265 0.0933 0.0949 0.96 (0.85–1.09) 0.52
t1:43 Age diagnosis b52
t1:44 ER−/PR− 1530 37,043 0.0980 0.0932 1.07 (0.95–1.22) 0.28
t1:45 ER−/PR−/ERBB2− 546 27,690 0.0908 0.0948 0.99 (0.81–1.20) 0.90
t1:46 BRCA1/2mutation negative 1431 1097 0.0853 0.0925 0.91 (0.75–1.11) 0.35
t1:47 BRCA1mutation carriers 7543 7222 0.0935 0.0919 1.04 (0.97–1.12) 0.27
t1:48 BRCA2mutation carriers 4138 3766 0.1005 0.0921 1.06 (0.94–1.19) 0.35
t1:49 Enrolled within two years of diagnosis
t1:50 All invasive 20,444 34,349 0.0924 0.0934 0.99 (0.95–1.04) 0.73
t1:51 BRCA1mutation carriers 2595 5976 0.0896 0.0924 0.95 (0.85–1.05) 0.30
t1:52 BRCA2mutation carriers 1359 3365 0.0960 0.0926 1.05 (0.90–1.23) 0.52
t1:53 Menopausal status
t1:54 Pre- or peri-menopausal 7086 8642 0.0934 0.0933 0.98 (0.91–1.07) 0.70
t1:55 Post-menopausal 16,346 18,605 0.0904 0.0943 0.98 (0.93–1.03) 0.36
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469 deleterious BRCA1 or BRCA2 mutations primarily identiﬁed through
470 clinical genetics centers. For the purpose of the current analyses, only
471 participants of European ancestrywere included. Following genotyping,
472 quality control exclusions (described below), and analysis-speciﬁc ex-
473 clusions, data from the following women were available for analysis:
474 46,173 OCAC participants (15,357 patients with invasive epithelial
475 ovarian cancer and 30,816 controls), 71,170 BCAC participants (33,530
476 patients with invasive breast cancer and 37,640 controls), and 22,669
477 CIMBA participants (for ovarian cancer analyses: 2332 affected and
478 12,433 unaffected BRCA1 carriers, 599 affected and 7305 unaffected
479 BRCA2 carriers; for breast cancer analyses: 7543 affected and 7222
480 unaffected BRCA1 carriers, 4138 affected and 3766 unaffected BRCA2
481 carriers). For OCAC, overall and progression-free survival data were
482 available for 3096 patients from 13 studies. Overall survival data were
483 available for 28,471 patients from 26 BCAC studies and for 2623
484 mutation carriers with breast cancer from 11 CIMBA studies (excluding
485 studies with less than ten deaths) as described previously [26,27]. Each
486 study was approved by its relevant governing research ethics commit-
487 tee, and all study participants provided written informed consent.
488 2.2. Genotyping and imputation
489 Genotyping for rs61764370 was performed using the custom iCOGS
490 Illumina Inﬁnium iSelect BeadChip, as previously described [22–25]. In
491 total, DNA from 185,443 women of varying ethnic background was ge-
492 notyped (47,630 OCAC participants, 114,255 BCAC participants, 23,558
493 CIMBA participants), along with HapMap2 DNAs for European, African,
494 and Asian populations. Genotype data were also available for three
495 OCAC genome-wide association studies (UK GWAS, US GWAS, Mayo
496 GWAS) that had been genotyped using either the Illumina
497 Human610-Quad Beadchip (12,607 participants) [28] or the Illumina
498 HumanOmni2.5-8 Beadchip (883 participants). Raw intensity data
499 ﬁles underwent centralized genotype calling and quality control
500 [22–25]. HapMap2 samples were used to identify women with predict-
501 ed European intercontinental ancestry; among these women, a set of
502 over 37,000 unlinked markers was used to perform principal compo-
503 nent (PC) analysis [29]. The ﬁrst ﬁve and seven European PCs were
504 found to control adequately for residual population stratiﬁcation in
505 OCAC and BCAC data, respectively. Samples with low conversion rate,
506 extreme heterozygosity, non-female sex, or one of a ﬁrst-degree relative
507 pair (the latter for OCAC and BCAC only) were excluded. Variants were
508 excluded if they were monomorphic or had a call rate b95% (minor al-
509 lele frequency (MAF) N0.05) or b99% (MAF b0.05), deviation from
510 Hardy–Weinberg equilibrium (p b 10−7), or N2% duplicate discordance.
511 In addition to rs61764370, 54 variants within 100 kb on either side
512 of KRAS on chromosome 12 (25,258,179 to 25,503,854 bp in
513 GRCh37.p12) were genotyped. Moreover, to provide a common set of
514 variants across the region for analysis in all the data sets, we also used
515 imputation to infer genotypes for another 1056 variants and for variants
516 that failed genotyping. We performed imputation separately for OCAC
517 samples, BCAC samples, BRCA1mutation carriers, BRCA2mutation car-
518 riers, and for each of the OCAC GWAS. We imputed variants from the
519 1000 Genomes Project data using the v3 April 2012 release as the refer-
520 ence panel [30]. To improve computation efﬁciency we initially used a
521 two-step procedure, which involved pre-phasing using the SHAPEIT
522 software [31] in the ﬁrst step and imputation of the phased data in the
523 second.We used the IMPUTE version 2 software [32] for the imputation
524 for all studies with the exception of the USGWAS for whichwe used the
525 MACH algorithm implemented in the minimac software version
526 2012.8.15 andMACHversion 1.0.18 [33].We excluded variants from as-
527 sociation analyses if their imputation accuracy was r2 b 0.30 or their
528 MAF was b0.005, resulting in 974 variants genotyped and imputed for
529 OCAC, 989 variants genotyped and imputed for BCAC, and 1001 variants
530 genotyped and imputed for CIMBA, including rs61764370 (Supplemen-
531 tary Tables S5, S6, and S7).
5322.3. Analysis
533Genotypeswere coded for genotype dosage as 0, 1, or 2, based on the
534number of copies of the minor allele. For ovarian cancer case–control
535analysis (i.e., OCAC studies), logistic regression provided estimated
536risks of invasive epithelial ovarian cancer with odds ratios (ORs) and
53795% conﬁdence intervals (CIs) adjusting for study, age, and the ﬁve
538European PCs. Subgroup analyses were conducted by histology, family
539ovarian and breast cancer history, menopausal status, time between
540ovarian cancer diagnosis and recruitment, and history of multiple
541primary cancers. For breast cancer case–control analysis (i.e., BCAC
542studies), the association between genotype and invasive breast cancer
543risk was evaluated by logistic regression, adjusting for study, age, and
544the seven European PCs, providing ORs and 95% CIs. Additional
545subgroup analyses were based on receptor status, ﬁrst-degree family
546ovarian and breast cancer history, BRCA1 and BRCA2 mutation status,
547enrollment within two years of diagnosis, menopausal status (i.e. last
548menstruation longer than twelve months ago), age at diagnosis less
549than 52 years, and history of hormone replacement therapy use (i.e. lon-
550ger than twelve months use). Risk analysis for BRCA1 and BRCA2muta-
551tion carriers (i.e. CIMBA studies) was done using a Cox proportional
552hazard model to estimate hazard ratios (HRs) per copy of the minor al-
553lele, with age as follow-up time and stratiﬁed by country of residence;
554US and Canadian strata were further subdivided by self-reported
555Ashkenazi Jewish ancestry [24,25]. Aweighted cohort approachwas ap-
556plied to correct for potential testing bias due to overrepresentation of
557cases in the study population [34]. We used robust variance estimation
558to allow for the non-independence of carriers within the same family
559[35]. To assess associations with ovarian cancer risk, mutation carriers
560were followed from birth until ovarian cancer diagnosis (event), a
561risk-reducing salpingo-oophorectomy (RRSO) or the age at enrollment,
t2:1Table 2
t2:2Associations between KRAS rs61764370 and outcome in ovarian and breast cancer.
t2:3Ovarian cancer analyses usedOCAC data adjusted for age at diagnosis (overall survival on-
t2:4ly), the ﬁve European principal components, histology (serous, mucinous, endometrioid,
t2:5clear cell, and other epithelial), grade (low versus high), FIGO stage (I–IV), residual disease
t2:6after debulking surgery (nil versus any), and stratiﬁed by study; breast cancer analyses
t2:7usedBCACdata adjusted for age at diagnosis, tumor size, nodal status, grade, adjuvant hor-
t2:8monal and/or chemotherapy and was stratiﬁed by study; analyses for BRCA1 and BRCA2
t2:9mutation carriers used CIMBA data adjusted for age at diagnosis, tumor size, nodal status,
t2:10grade, adjuvant hormonal and/or chemotherapy, and preventive bilateral oophorectomy
t2:11and was stratiﬁed by study; 95% CI, 95% conﬁdence interval.
t2:12No. of
patients
No. of
events
Hazard ratio
(95% CI)
p-Value
t2:13Ovarian cancer
t2:14Overall survival
t2:15All patients 3096 1421 0.94 (0.83–1.07) 0.38
t2:16Patients who were suboptimally
t2:17debulked after cytoreductive
surgery
1114 784 0.94 (0.78–1.13) 0.50
t2:18Post-menopausal patients N 52
years
2226 1276 0.97 (0.84–1.12) 0.70
t2:19Progression-free survival
t2:20All patients 3096 2144 1.01 (0.90–1.13) 0.84
t2:21Patients who were suboptimally
t2:22debulked after cytoreductive
surgery
1114 961 1.03 (0.87–1.21) 0.74
t2:23Post-menopausal patients N52
years
2226 1603 1.02 (0.90–1.16) 0.76
t2:24
t2:25Breast cancer
t2:26Overall survival
t2:27All patients 28,471 3013 0.96 (0.87–1.06) 0.38
t2:28ER-positive patients 20,071 1754 0.96 (0.85–1.10) 0.58
t2:29ER-negative patients 4778 771 0.97 (0.81–1.18) 0.78
t2:30Breast cancer-speciﬁc survival
t2:31All patients 28,471 1693 0.95 (0.83–1.08) 0.40
t2:32Overall survival
t2:33BRCA1mutation carriers 1706 241 0.72 (0.48–1.08) 0.11
t2:34BRCA2mutation carriers 917 162 0.98 (0.65–1.46) 0.90
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Fig. 1. Regional association plots for variants within the genomic region 100 kb either side of KRAS and risk of ovarian and breast cancer. X-axis position is referent to position (bp) on
chromosome 12, build GRCh37.p12; yellow line indicates position of KRAS; red triangle indicates rs61764370. Y-axis is−log10(p-values) from association tests for risk of A) ER-negative
breast cancer, B) ER-positive breast cancer, C) breast cancer in BRCA1mutation carriers, D) breast cancer in BRCA2mutation carriers, E) epithelial ovarian cancer, F) epithelial ovarian can-
cer in BRCA1mutation carriers, and G) epithelial ovarian cancer in BRCA2mutation carriers. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the
web version of this article.)
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562 whichever occurred ﬁrst. We also performed analyses restricted to
563 women diagnosed or censored within two years before their enroll-
564 ment. To assess associations with breast cancer risk, mutation carriers
565 were followed from birth until a breast cancer diagnosis (i.e. either duc-
566 tal carcinoma in situ or invasive breast cancer), ovarian cancer diagno-
567 sis, a risk-reducing bilateral prophylactic mastectomy or the age at
568 enrollment, whichever occurred ﬁrst.
569 Survival analysis of OCAC patients used Cox proportional hazards
570 models estimating HRs and 95% CIs considering overall survival as
571 well as progression-free survival following ovarian cancer diagnosis.
572 Overall survival was adjusted for age at diagnosis, the ﬁve European
573 PCs, histology, grade, FIGO stage, andQ7 residual disease after debulking
574 surgery, and stratiﬁed by study, left truncating at the date of study
575 entry and right censoring at ﬁve years to minimize events due to
576 other causes. Progression-free survival was analyzed as for overall
577 survival, but without adjustment for age and right censoring, and was
578 deﬁned as the time between the date of histologic diagnosis and the
579 ﬁrst conﬁrmed sign of disease recurrence or progression, based on
580 GCIG (Gynecological Cancer InterGroup) criteria [36].We also performed
581 subgroup analysis of patients suboptimally debulked after cytoreductive
582 surgery (residual disease N1 cm) and of post-menopausal patients (age
583 at diagnosis N52 years). Survival analysis of BCAC patients used Cox pro-
584 portional hazard models estimating HRs and 95% CIs considering overall
585 and breast cancer-speciﬁc survival following breast cancer diagnosis.
586 Models were adjusted for age at diagnosis, tumor size, nodal status,
587 grade, adjuvant hormonal and/or chemotherapy, and stratiﬁed by
588 study, left-truncating at the date of study entry and right censoring at
589 ten years. In addition, we performed subgroup analysis on ER-positive
590 and ER-negative patients. For CIMBA breast cancer patients associations
591 between genotype and overall survival were evaluated using Cox
592 proportional hazard models estimating HRs and 95% CIs. Models were
593 adjusted for age at diagnosis, tumor size, nodal status, grade, adjuvant
594 hormonal and/or chemotherapy, and preventive bilateral oophorectomy
595 and stratiﬁed by study, left-truncating at the date of study entry and right
596 censoring at twenty years. Analyses were performed using STATA ver-
597 sion 12.0 (StataCorp, Texas, USA).
598 3. Results
599 The results of the overall analysis as well as the subgroup analyses
600 investigating the association between the minor allele at rs61764370
601 and ovarian cancer risk, breast cancer risk, and ovarian and breast
602 cancer risks in BRCA1 and BRCA2 mutation carriers are shown in
603 Table 1. Associations with clinical outcomes in and ovarian and breast
604 cancer patients including BRCA1 and BRCA2 mutation carriers are
605 shown in Table 2 and Supplementary Table S4.
606 We found no evidence for association between the rs61764370 G al-
607 lele and ovarian or breast cancer risk. The most statistically signiﬁcant
608 association was observed for risk of low-grade serous ovarian cancer
609 (n = 485; OR 0.76, 95% CI 0.59–0.97, p = 0.031), but this ﬁnding was
610 not signiﬁcant after Bonferroni correction for multiple testing. We also
611 evaluated the association for additional speciﬁc subgroups in which an
612 association with rs61764370 had been reported previously [3–6]. Ovar-
613 ian cancer subgroups considered BRCA1 mutation carriers as well as
614 BRCA1 and BRCA2 screened-negative patients with ﬁrst degree family
615 histories of breast or ovarian cancer and patients who had been diag-
616 nosed with breast cancer before their ovarian cancer diagnoses. For
617 breast cancer these included, among others, BRCA1 mutation carriers,
618 patients diagnosed with ER- and PR-negative tumors, and patients
619 diagnosed with triple negative tumors before age 52 years. Importantly,
620 we observed no evidence for association of rs61764370 with any of
621 these subgroups (detailed in Table 1), with all ORs close to unity and
622 very narrow CIs including unity.
623 Similarly, case-only analyses did not reveal any associations
624 between rs61764370 genotype and ovarian and breast cancer clinical
625 features or outcome (Table 2 and Supplementary Table S4). For
626example, the previously reported association between rs61764370
627and risk of ERBB2-positive and high grade breast cancer in hormone re-
628placement therapy users [18] was not replicated (Supplementary
629Table S4), and in ovarian cancer analyses we found no evidence of re-
630duced survival among patients diagnosed after age 52 years or patients
631with suboptimal debulking after cytoreductive surgery (Table 2) [14].
632The G allele of rs61764370 was also not associated with survival of
633breast cancer patients (Table 2).
634Finally, we evaluated the association between the primary pheno-
635types of interest and common genetic variation (MAF N 0.02) in the ge-
636nomic region of KRAS (i.e., within 100 kb on either side of the gene),
637using imputed and genotyped data on 974 variants for OCAC, 989 vari-
638ants for BCAC, and 1001 variants genotyped and imputed for CIMBA
639(Supplementary Tables S5, S6, and S7). We found no evidence of associ-
640ation for any of these variants, including rs61764370 and rs17388148,
641with these phenotypes that would withstand Bonferroni correction for
642multiple testing, as detailed in Supplementary Tables S5, S6, and S7
643and shown in regional association plots (Fig. 1).
6444. Discussion
645Our analysis of 140,012 women genotyped for inherited variants in
646the KRAS region provides deﬁnitive clariﬁcation of the role of these var-
647iants in ovarian and breast cancer susceptibility and outcome. We have
648found no evidence to support an association between rs61764370 and
649ovarian or breast cancer risk, or clinical outcomes in patients with ovar-
650ian or breast cancer. In the absence of any association and with ORs
651close to unity we would not typically consider sub-group analyses, par-
652ticularly sub-groups forwhich differential associationswould not be ex-
653pected to occur. However, given the previous positive associations
654reported for a myriad of different subgroups, we tested for association
655among each of these subgroups and found no evidence to support the
656previously reported associations.
657Our study has notable strengths. The vast majority (i.e. N95%) of the
658samples were genotyped using the same genotyping platform and
659employing a common approach to genotype calling and quality control;
660additional samples used denser arrays and nearly identical procedures.
661The very large sample sizes for all themajor phenotypes of interest pro-
662vide substantial statistical power to exclude any clinically relevant asso-
663ciated risks for themajor phenotypes of interest (Fig. 2). The null results
664found here are thus not due to lack of statistical power, and this analysis
665also had greater than 80% power to detect association for most of the
666subgroups, although for some subgroups it was not possible to exclude
Fig. 2. Power curve for modest risk variants according to the total sample size. X-axis is
total sample size for which case–control ratio is 1:1. Y-axis is the statistical power
(range 0 · 5–1 · 0) for variants given a range of risks, assuming alpha = 0 · 01 and
minor allele frequency 0 · 09.
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667 modest risks. In contrast to the current ﬁndings, other genetic associa-
668 tion analyses using the same genotyping platform and the same studies
669 as included here have identiﬁed more than 90 common germline
670 variants associated with ovarian or breast cancer risk at p b 5 × 10−8
671 [22,23,37]. While critiques on a previous null KRAS report have sug-
672 gested that inclusion of male controls, use of “prevalent” cases, and reli-
673 ance on a surrogate genetic variant may have led to falsely negative
674 conclusions, these are not issues in the present data set. Rather, we
675 demonstrate the importance of international collaboration to identify
676 true associations aswell as to refute false associations, an equally impor-
677 tant objective.
678 The rise of individualized medicine including the use of panels of
679 common variants to predict cancer riskmore accurately than using fam-
680 ily history alone holds great promise [38]. For example, the 31 prostate
681 cancer susceptibility alleles conﬁrmed as of 2011 (at p b 5 × 10−8) can
682 be combined to identify men in the top one percent of the risk distribu-
683 tion having a 3.2-fold increased risk [39]. Prediction has since then im-
684 proved with now over 70 prostate cancer susceptibility alleles [40]
685 and the utility of these genetic tests is currently under clinical evalua-
686 tion. A similar clinical examination in ovarian and breast cancer is not
687 far behind, with now over 18 and 77 conﬁrmed susceptibility alleles, re-
688 spectively, for these cancers [22,23]. The genotype at rs61764370, how-
689 ever, does not predict ovarian or breast cancer risk, even among
690 particular subgroups of women or for particular subtypes of disease,
691 nor is it a marker of differential outcome following diagnosis with
692 these cancers. Therefore, genetic test results for rs61764370 should
693 not be used to counsel women about their ovarian or breast cancer
694 risks or outcome.Our results highlight the dangers of developing clinical
695 tests without appropriate data from carefully conducted, large-scale
696 studies to establish clinical validity.
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